Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| (In thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of marketable securities | (156,901) | (141,423) |
| Proceeds from maturities of marketable securities | 141,280 | 136,906 |
| Proceeds from sale of property and equipment | 9 | 56 |
| Purchase of property and equipment | (4,384) | (2,426) |
| Purchase of intangible assets | (61) | (76) |
| Net cash (used in) investing activities | (20,057) | (6,961) |
| Cash flows from financing activities: | ||
| Repayment of loan | (2,482) | (1,660) |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s capex?
- Cytek Biosciences, Inc. (CTKB) reported capex of $2.22M in Q2 2026.
- How has Cytek Biosciences, Inc.'s capex changed year-over-year?
- Cytek Biosciences, Inc.'s capex increased by 40.5% year-over-year, from $1.58M to $2.22M.
- What is the long-term trend for Cytek Biosciences, Inc.'s capex?
- Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s capex has grown at a -1.6% compound annual growth rate (CAGR), from $4.36M to $4.08M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Cytek Biosciences, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude